|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 08-03 | Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH | MT |
| 08-03 | Altimmune, Inc. Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH | CI |
| Market Cap | 597M 518M 483M 444M 840M 56.79B 849M 5.7B 2.23B 28.39B 2.24B 2.19B 94.07B | P/E 2026 * |
-4.98x | P/E 2027 * | -4.58x |
|---|---|---|---|---|---|
| Enterprise Value | 153M 132M 123M 113M 215M 14.51B 217M 1.46B 569M 7.25B 573M 560M 24.03B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
99.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Altimmune Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Jerome Durso
CEO | Chief Executive Officer | 58 | 01/01/2026 |
Gregory Weaver
DFI | Director of Finance/CFO | 70 | 11/11/2024 |
Rachel Garner
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Philip Hodges
BRD | Director/Board Member | 58 | 01/09/2003 |
Mitchel Sayare
CHM | Chairman | 78 | 01/01/2018 |
Klaus Schafer
BRD | Director/Board Member | 76 | 01/07/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.00% | +14.90% | +53.89% | +87.07% | 62.53B | |
| +1.21% | -5.05% | +22.94% | +66.57% | 52.43B | |
| -0.98% | -1.19% | -16.98% | -14.21% | 23.1B | |
| +0.30% | -5.17% | -11.23% | +349.07% | 21.4B | |
| -0.40% | +0.40% | +30.99% | -26.23% | 17.76B | |
| +4.29% | +8.97% | +200.03% | +341.85% | 15.47B | |
| +1.41% | -1.93% | +12.70% | +607.25% | 14.68B | |
| +1.71% | -0.90% | +52.13% | +176.27% | 14.08B | |
| +4.16% | +4.44% | +444.12% | +183.06% | 12.62B | |
| Average | +2.41% | +0.99% | +87.62% | +196.74% | 26.01B | |
| Weighted average by Cap. | +3.53% | +1.83% | +60.28% | +147.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -107M -92.87M -86.59M -79.54M -150M -10.17B -152M -1.02B -399M -5.09B -402M -393M -16.85B | -130M -113M -105M -96.7M -183M -12.37B -185M -1.24B -485M -6.18B -488M -478M -20.48B |
| Net Debt | -444M -386M -360M -331M -625M -42.28B -632M -4.24B -1.66B -21.14B -1.67B -1.63B -70.03B | -340M -295M -275M -253M -478M -32.32B -483M -3.24B -1.27B -16.16B -1.28B -1.25B -53.54B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
